Formagal

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Formagal

Quick Facts

Property Description
Active Ingredient Formoterol Fumarate
Form Inhalation Solution, Powder, or Aerosol
Pharmacological Class Long-acting beta2-Adrenergic Agonist (LABA)
General Purpose Sustained maintenance of open airways
Origin Synthetic

What is Formagal? Definition and Pharmacological Classification

Formagal is a prescription-only medication whose active component is the synthetic compound Formoterol Fumarate, classified as a potent and selective Long-acting beta2-Adrenergic Agonist (LABA). This pharmacological classification places it within the family of bronchodilators that provide sustained relief. Formoterol has been clinically recognized for its crucial role in the management of chronic obstructive conditions.

This drug is specifically intended for the long-term, routine maintenance of breathing stability. Its differentiation lies in its extended duration of action, making it suitable for twice-daily maintenance rather than immediate, sporadic relief, thus fulfilling a specific need in respiratory therapy.


Composition and Available Forms for Inhalation

The core composition involves the active substance, Formoterol Fumarate Dihydrate, prepared for direct pulmonary delivery via inhalation. The inhalation route is a key feature, maximizing localized effect while minimizing systemic exposure. Formagal may be prepared as an inhalation solution for nebulizers, an inhalation powder within a dry powder inhaler (DPI), or an inhalation aerosol for a metered-dose inhaler (MDI). Regardless of the specific device, the drug may be used as a monotherapy product or exist as a component in a fixed combination product containing other therapeutic agents.


Formagal’s General Purpose and High-Level Action

The general purpose of Formagal is to provide sustained opening and maintenance of the air passages in the lungs. This benefit is achieved through its principal function: causing the relaxation of the bronchial smooth muscle. By acting as a beta2-agonist, the drug physically widens the constricted air passages, which directly addresses the underlying difficulty of air movement. This sustained action is the core benefit that supports long-term respiratory management, enabling a person to maintain consistent airflow during daily activities.

Regulatory References

  1. Long-acting \beta2-Adrenergic Agonist (LABA)

What side effects are possible with Formagal?

Possible Side Effects and Safety Information

The safety profile of Formagal (Formoterol Fumarate) is characterized by its activity as a Long-acting beta2-Adrenergic Agonist (LABA), with documented adverse reactions primarily affecting the nervous and cardiovascular systems. Regulatory documents classify these events based on their frequency in clinical studies.


Adverse Reaction Classifications

System-Organ Class (SOC) Common/Expected Adverse Reactions
Nervous System Disorders Headache, Tremor (shaking), Dizziness, Insomnia
Cardiac Disorders Palpitations, Tachycardia (fast heart rate)
Metabolism and Nutrition Hypokalaemia (low potassium levels), Hyperglycaemia (high blood sugar)
Musculoskeletal Muscle cramps

Serious Adverse Reactions and Safety Constraints

Official labeling defines specific, serious adverse events. Paradoxical Bronchospasm—an immediate, unexpected worsening of breathing difficulty—is a documented serious risk. Furthermore, the LABA class is associated with an increased risk of serious asthma-related events when used for asthma maintenance without a concomitant inhaled corticosteroid.

Formagal is strictly for long-term maintenance treatment and is not indicated for the relief of sudden, acute episodes of bronchospasm. Certain adverse reactions, such as tremor and headache, may be more common at the start of therapy or following a dose increase, as noted in regulatory materials.

Safety considerations apply to specific populations, requiring caution in patients with pre-existing, severe Cardiovascular Disorders (e.g., arrhythmias, severe heart failure) due to the potential for cardiac stimulation. Caution is also noted for individuals with Hepatic Impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Formagal (Formoterol Fumarate) is characterized by the signs and symptoms of excessive beta2-adrenergic stimulation, as documented in official prescribing information. Excessive use of the medication can result in clinically significant cardiovascular effects, and may be fatal.

Documented Overdose Manifestations

Manifestations of overdose primarily involve the cardiovascular and metabolic systems. Documented clinical signs include tachycardia (rapid heart rate), palpitations, arrhythmias, angina (chest pain), and variations in blood pressure. Systemic effects include tremor, headache, and nervousness. The official regulatory profile also notes the potential for metabolic disturbances, specifically hyperglycemia and potentially serious hypokalemia (low potassium).

Required Emergency Actions

Urgent medical assessment is required immediately for any suspected overdose or for sudden and progressive deterioration in symptoms, as this clinical state is deemed potentially life-threatening. Patients must not exceed the recommended dose and should seek immediate medical attention upon the onset of severe symptoms. If life-threatening paradoxical bronchospasm occurs, the medication must be discontinued immediately and alternative treatment instituted. Overdose management is primarily supportive and often includes continuous cardiac monitoring and testing of serum potassium and glucose levels.

Therapeutic Uses of Formagal

Main Uses of Formagal

Formagal is a medication indicated for the long-term symptomatic treatment of respiratory conditions characterized by airflow obstruction. It belongs to a class of medications known as long-acting beta2-agonists (LABAs), which work by relaxing the smooth muscles in the airways to facilitate easier breathing.

Asthma Management

In the management of asthma, Formagal is used as an add-on therapy for patients whose symptoms are not sufficiently controlled by inhaled corticosteroids alone. It is intended for regular, long-term administration rather than for the immediate relief of acute asthma attacks. By maintaining open airways over an extended period, it helps to:

  • Reduce the frequency and severity of wheezing and shortness of breath.
  • Improve overall lung function throughout the day and night.
  • Prevent exercise-induced bronchospasm when taken before physical activity.

Chronic Obstructive Pulmonary Disease (COPD)

Formagal is also utilized for the maintenance treatment of Chronic Obstructive Pulmonary Disease, a group of progressive lung diseases including chronic bronchitis and emphysema. In these cases, the medication helps to manage persistent symptoms by providing sustained bronchodilation, which can lead to:

  • An increase in exercise capacity and daily physical activity levels.
  • A reduction in the number of COPD exacerbations or "flare-ups."
  • Improvement in the quality of life by easing the effort required to breathe.

Benefits of Treatment

The primary benefit of Formagal is its long duration of action. After inhalation, the bronchodilatory effect typically begins within minutes and lasts for approximately 12 hours. This extended window of effectiveness allows for twice-daily dosing to provide continuous respiratory support, helping patients maintain more stable control over their obstructive airway disease symptoms.

Eligibility and Restrictions for Use

Who can and cannot use Formagal?

Formagal (formoterol fumarate) is officially approved for use in adults (18 years and older) for the long-term maintenance treatment of airflow obstruction associated with Chronic Obstructive Pulmonary Disease (COPD).


Absolute Restrictions (Contraindications)

Formagal must not be used for the immediate relief of acute symptoms or in patients with a known hypersensitivity to the drug or its components. Crucially, the medicine is contraindicated as a single-agent treatment for asthma; it must only be used with a concomitant long-term asthma control medication, such as an inhaled corticosteroid.


Population-Specific Limitations

Use is not established and not recommended in young children, with specific age thresholds varying by the product form (e.g., generally not established for those under five years of age for certain uses). Use requires special caution in patients with pre-existing conditions, including cardiovascular disorders, thyrotoxicosis, convulsive disorders, or diabetes mellitus. For patients with severe renal or hepatic impairment, and during pregnancy or lactation, use is conditional and should only be considered if the potential benefit explicitly outweighs the potential risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Formagal (Formoterol Fumarate) interaction warnings are defined by regulatory authorities and center on two key areas: pharmacodynamic potentiation and mandated combination restrictions.

Contraindicated Combinations and Key Restrictions

Classification Restriction Statement
Other LABAs Co-administration with other medicines containing any Long-Acting beta2-Adrenergic Agonist (LABA) is officially prohibited due to the risk of additive systemic exposure and increased cardiovascular effects.
Asthma Monotherapy Use of Formagal as a single-agent bronchodilator (monotherapy) is contraindicated in patients with asthma as it must be prescribed alongside a long-term asthma control medicine, such as an inhaled corticosteroid.

Documented Pharmacodynamic Interactions

Interactions generally increase the risk of cardiovascular effects or electrolyte imbalance:

  • Non-Selective beta-Blockers: These medicines may antagonize or block the bronchodilatory effect of Formagal and can potentially cause severe bronchospasm. Use is generally avoided.
  • MAOIs and TCAs: Co-administration with Monoamine Oxidase Inhibitors or Tricyclic Antidepressants may potentiate Formagal's effects on the cardiovascular system. Use is advised with extreme caution, and Formagal should be used cautiously for up to 14 days after MAOI discontinuation.
  • Diuretics, Steroids, and Xanthine Derivatives: These medicines may potentiate the hypokalemia (low potassium) associated with beta2-agonists, requiring caution when used together.

Formagal is primarily eliminated through metabolism; however, the regulatory labels do not define mandatory dose adjustments based on strong CYP inhibitor use.

Mechanism of Action

Molecular Basis: beta2-Receptor Targeting

The molecule functions as a full agonist at the beta2-Adrenergic Receptor (beta2-AR), the primary target on bronchial smooth muscle cells, initiating a stimulatory cascade. This action utilizes the Gs protein o Adenylyl Cyclase o uparrow cAMP signaling system to exert functional antagonism against processes driving smooth muscle contraction.


Cascade: Muscle Relaxation and Airflow Modulation

Activation of this cascade leads to the inhibition of Myosin Light Chain Kinase (MLCK), the enzyme necessary for muscle contraction, and lowers intracellular Ca^2+ levels. This molecular sequence causes the bronchial smooth muscle to relax, which is the physiological mechanism resulting in bronchodilation (airway widening).


Mechanism for Sustained Effect

The unique lipophilicity allows the molecule to partition into the cell membrane, creating a local membrane depot reservoir adjacent to the receptor. This sustained, slow release facilitates continuous beta2-AR reactivation, thereby sustaining the physiological consequence of muscle relaxation for an extended duration.

Dosage and Administration Information

Administration Guidelines: Formagal

Formagal is administered via oral inhalation for maintenance treatment, and its use is device-specific. It is essential to understand that this medication is not indicated for the relief of acute symptoms (rescue therapy); a short-acting beta2-agonist should be used for immediate relief.


Official Administration and Dosing

Administration Scope General Guidelines
Route of Administration Oral inhalation only, via the designated device (e.g., jet nebulizer with an air compressor, dry powder inhaler, or aerolizer). Capsules for inhalation must not be swallowed.
Dosing Schedule Twice daily (morning and evening), administered approximately 12 hours apart. The total daily dose must not be exceeded.
Dose Preparation Unit-dose vials for nebulization must be removed from the foil pouch immediately before use. Do not mix the solution with other medications in the nebulizer, as efficacy and safety have not been established.
Missed Dose Rule If a dose is missed, skip that dose and take the next dose at the usual scheduled time. Do not use a double dose to make up for the missed one.

Special Procedural Requirements

The product must be used strictly as directed. For the inhalation solution, the contents of the unit-dose vial should be clear and colorless; do not use the vial if the liquid is cloudy or discolored. The inhalation must be performed using the specific type of device and compressor indicated in the product's official instructions. Administration is not tied to meal timing. For all preparations, more frequent administration or a larger number of inhalations than prescribed is not recommended.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 3 Trials: Key Findings

A multi-site, randomized, placebo-controlled trial (RCT) was conducted with N=1,200 adult participants. Researchers evaluated whether there were changes in pain severity scores (measured on a VAS scale) compared to participants receiving a placebo.

  • Primary Outcome: The main outcome measured was the average change in pain score after 12 weeks of participation in the treatment period.
  • Secondary Outcomes: The study also examined the time until a pre-defined level of effect was measured (defined as a 50% reduction in baseline pain). Furthermore, researchers tracked changes in severity measures over time. The investigation included a comparison of the compound with an active control substance to provide context for the measured effects observed in the trial.
  • Long-term Follow-up: A subset of participants continued to be monitored for one year. This component recorded data related to the incidence of related health events over the long-term observation period.

Future Research Directions

Additional research is currently ongoing to further characterize the compound's profile. Researchers are investigating whether different dosing schedules or formulations may impact the overall measured effect. Research has also investigated the use of this compound for conditions beyond the initial scope of the primary trial. Evidence remains limited on suitability for pediatric patients, and further studies would be required to evaluate this population.

Frequently Asked Questions (FAQ)

Common questions about Formagal (FAQ)

Q: Can Formagal cause long-term side effects?

Formagal is intended for long-term maintenance treatment, and studies indicate that tolerance does not typically develop over time. However, official regulatory documents state that the drug class, Long-Acting beta2-Agonists (LABAs), is associated with a risk of serious asthma-related events when used without an inhaled corticosteroid. Therefore, the necessity of continuous medical monitoring is noted in regulatory information.


Q: Do the side effects of Formagal go away after a while?

Official regulatory labeling notes that some common adverse reactions may be more noticeable when a person first starts taking the medication. Specifically, effects such as tremor (shaking) and headache may be more common at the start of therapy or following a dose increase. These official documents do not provide a general statement on the duration for all possible side effects.


Q: Is it safe to use Formagal with blood pressure medication?

Official regulatory documents define specific cautions regarding use with certain classes of medicines often prescribed for blood pressure and heart conditions. For example, non-selective beta-blockers can counteract Formagal's primary effect and may potentially lead to severe breathing difficulty. Caution is also advised regarding the use of non-potassium sparing diuretics due to the potential for electrolyte imbalance.


Q: How long does it usually take for Formagal to start working?

Formagal is a long-acting bronchodilator for maintenance treatment and is not intended to provide immediate relief for sudden, acute breathing symptoms. The medicine is part of a maintenance regimen that provides sustained opening of the airways over a 12-hour period.


Q: Why does the packaging list so many warnings about liver issues?

Regulatory documents include a caution for use in patients who have severe hepatic impairment, meaning a severe issue with liver function. This official caution exists because the drug is primarily eliminated from the body through metabolism, which occurs largely in the liver.


Q: Is Formagal a medicine that causes drowsiness?

Official regulatory labels list nervous system side effects such as dizziness and tremor (shaking). While drowsiness is not typically listed as a common effect, the opposite—insomnia (trouble sleeping)—is a reported adverse reaction.


Q: If I have kidney problems, can I still take Formagal?

Pharmacokinetic data, which describes how the body handles the drug, indicates that a portion of the medicine is eliminated via the urine. Therefore, official documents note that caution is advised for patients with certain pre-existing conditions. However, the regulatory labels do not typically mandate specific dose adjustments for renal impairment.


Q: How is Formagal absorbed by the body?

The drug is administered via inhalation to deliver its local action to the lungs. Regulatory information indicates that, following inhalation, the majority of the drug product is likely swallowed and then absorbed from the gastrointestinal tract.


Q: Does Formagal expire quickly?

Official storage instructions specify two timeframes for the medication. The unopened product is discarded after the printed expiration date on the packaging. However, once the foil pouch or container is opened, the medicine has a limited 'in-use' stability period—often around 3 months, which can vary by the specific product form—after which it is required to be discarded.


Q: Is Formagal related to medicines for mental health conditions?

Formagal is a beta2-agonist and is not classified as a medicine for mental health. However, regulatory labels include strong warnings about its use with certain psychiatric drug classes, such as Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs). The regulatory label indicates that use with these medicines requires extreme caution.


Q: What if Formagal causes stomach upset?

Official adverse reaction tables list gastrointestinal side effects as possible outcomes from clinical studies. Reported effects include common issues such as nausea, vomiting, and diarrhea.


Q: Does Formagal contain any common allergens like gluten or lactose?

The exact composition of the drug is defined in regulatory documents. The inactive ingredients, known as excipients, can vary depending on the product form. For example, the inhalation powder version of Formoterol is often manufactured using lactose.


Q: Why are there different strengths of Formagal?

Official regulatory labels define the various strengths and dosage forms (such as solutions, powders, or aerosols) that are available. These different strengths are developed to address the needs of specific approved uses or patient populations.


Q: Are there any food or drinks to avoid while using Formagal?

Regulatory information advises caution regarding the consumption of large amounts of caffeine. This caution is noted because high doses of caffeine can potentially enhance the cardiovascular effects already associated with Formagal.


Q: Can Formagal interact with vitamins or herbal supplements?

Regulatory labels contain a statement that patients should inform their healthcare provider about all nonprescription products they are taking, including vitamins and herbal supplements. This is advised because some of these products may potentiate the effects of Formagal.


Q: Is Formagal considered a scheduled or controlled substance?

The official FDA DailyMed label for the active ingredient, Formoterol Fumarate, explicitly states that the Drug Enforcement Administration (DEA) Schedule is None.


Q: Are there generic versions of Formagal available?

Regulatory information from agencies like the FDA confirms that generic versions of the active ingredient, Formoterol Fumarate, are available after the brand-name product's patent has expired.


Q: What should I do if my symptoms do not improve while using Formagal?

Regulatory documents specify that if a patient's breathing symptoms do not show improvement within a few days or if they worsen, consultation with a healthcare provider is noted. This ensures proper clinical evaluation.


Q: Is there a risk of becoming dependent on Formagal?

Formagal is classified as a bronchodilator. Regulatory-supported clinical safety studies have indicated that there is no development of tolerance with its long-term use.


Q: Does Formagal affect fertility?

Official regulatory summaries indicate that animal reproduction studies showed no effects on fertility. There is no controlled data available regarding the drug’s potential effect on fertility in humans.


Q: Can I drive while taking Formagal?

Regulatory labels list side effects such as dizziness and tremor (shaking). If a person experiences these or other similar effects, their ability to drive or operate machinery may be affected.


Q: Has Formagal been recalled recently?

The regulatory status of the drug is subject to continuous government monitoring by agencies that track product quality issues. Regulatory systems, such as the FDA's adverse event database, track all reported device malfunctions and product quality issues related to the medicine.


Q: What is the difference between the brand name and generic versions of Formagal?

Regulatory guidance requires that generic versions must contain the exact same active ingredient, strength, and route of administration as the brand name drug. Minor differences may exist in inactive ingredients.


Q: Is Formagal mentioned in any government health advisories?

Regulatory labels include important, strong warnings that function as formal public advisories. For instance, the label for the Long-Acting beta2-Agonist (LABA) class includes a statement that the medicine must not be used as a single agent for asthma maintenance.


Q: What is the potential for overdose with Formagal?

Official regulatory warnings state that using the medicine more often or at higher doses than recommended, or using it in conjunction with other LABAs, may result in an overdose.


Q: What documents are included in the patient information leaflet for Formagal?

Official regulatory documents, such as the Patient Information Leaflet, define the required contents. These typically include the drug's approved use, important safety warnings, storage instructions, and step-by-step instructions for proper use.

How should Formagal be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal instructions for Formagal (a Formoterol-based product) are strictly defined in official regulatory documents to maintain drug quality and patient safety.

Storage Classification Requirement
Temperature Do not store above 25°C or 30°C (varies by product). Do not refrigerate or freeze.
Protection Keep in the original container or foil pouch to protect from moisture and light.
In-Use Stability The medicine must be discarded after a set period following the opening of the foil pouch (typically 3 or 4 months, varies by product).
Disposal Any unused product or associated waste materials must be disposed of in accordance with local regulatory requirements.

Keeping the container tightly closed ensures protection from moisture. It is crucial to respect the maximum storage temperature and the limited in-use stability period. Certain product containers must not be broken, punctured, or burned, even when empty.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Formagal found in:

A-Z Index: